Simultaneous estimation of ezetimibe and lovastatin by derivative spectroscopy

International Journal of PharmTech Research

Volumn 1, Issue 3, 2009, Pages 894-899

  Rajput, S J ^a   Raj, H A ^b  

^a M S UNIVERSITY OF BARODA   (India)

^b Shri Sarvajanik Pharmacy College   (India)

Author keywords

Ezetimibe; First derivative zerocrossing; Lovastatin; Simultaneous determination; Spectroscopic determination

Indexed keywords

EZETIB; EZETIMIBE; MEVINOLIN; STATIN; UNCLASSIFIED DRUG;

ABSORPTION SPECTROSCOPY; ACCURACY; ANALYTIC METHOD; ARTICLE; CALIBRATION; CONTROLLED STUDY; CORRELATION COEFFICIENT; DERIVATIVE SPECTROSCOPY; DRUG DETERMINATION; DRUG SENSITIVITY; LINEAR SYSTEM; POWDER; REPRODUCIBILITY; TABLET FORMULATION;

EID: 77953390727     PISSN: None     EISSN: 09744304     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Rosenblum S. B and Huynh T : Discovery off 1-(4-flurophenyl)-(3R)-[(4- flurophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetididnone (SCH 58235) a designed, potent, orally active inhibitor of cholesterol absorption, J. Med. Chem. 1998, 41, 973 -980.
2. Van H. M and France C. F: In vivo metabolism based discovery of a potent cholesterol absorption inhibitor, SCH 58235, in the rat and rhesus monkey through the identification of the active metablistes of SCH 48461, J Pharmacol. Exp. Ther. 1997, 283, 157-163.
3. Jones P. H and Davidson M. H: comparison of the efficacy and safety of rosuvastatin versus atrovastatin , simvastatin and proavastatin across doses, J Am. Cardio. 2003, 92, 152-160.
4. Davidson M. H and McGarry T: Ezetimibe co-administered with simvastatin in patient with primary hypercholesterolemia. J. Am. Cardio. 2000, 40, 2125-2134.
5. Ballantyne C. M and Houri J: Effect of Ezetimibe co-administered with atorvastatin in 628 patients with primary hyperchloesterolemia, a prospective, randomized, double blind trial. Circulation. 2003, 107, 2409-2415.
6. Mauro V. F and Tuckerman C. E: Ezetimibe for management of hyperchloesterolaemia. Amm. Pharmacother. 2003, 37, 839-848.
7. Vijiayvergia R and Sridhar G: Ezetimibe a novel cholesterol absorption inhibitor. Drug. Bul. 2001, 29(1), 35-41.
8. British Pharmacopoeia, Publ. The stationary office, Vol. 2, 1062.
9. Pillai A. D and Ravishnkara M. N: High performance thin layer chromatographic method for estimation of Lovastatin from tablets. Ind. J. Phar. Sci. 2000, 41, 420-423.
10. Siamak M. S and Mohammad R. B: Screening of Lovastatin production by filamentans fungi. Iran. Biomed. J. 2003, 7 (1), 29-33.
11. Sistla R and Tata V.S: Development and validation of reversed -phase rHPLC method for the determination of ezetimibe in pharmaceutical dosage forms. J. Pharm. Bio. Anal. 2005, 39(3-4), 517-522.
12. Ghosal A and Hapangama N: Identification of human UDP- Glucuronosyltransferase enzyme(s) responsible ofrhte glucuronidation of ezetimibe. D. M. D. 2002. 32. 314-320.
13. James E. P and Kosoglou T: Disposition of the selective cholesterol absorption inhibitor ezetimibe in heatlthy male subject. D. M. D. 2002, 30(4), 430-437.
14. Van H.M and Farley C: Ezetimibe potently inhibit chlesterol absorption but dose not affect acute hepatic or intestinal cholestero sysnthsis in rates, J. Brit. Pharmaco. 2003, 138, 1459-1464.
15. Karpinska J and Mulikowska M: Simultaneous determination of zinc (II) manganese II and iron (II) in pharmaceutical prepatations, J. Pharm. Bio. Anal. 2002, 29, 153-158.
16. 12 and uridin 5'-triphosphate, by derivative spectrophotometry. J. Pharm. Sci. 1995, 84(1), 34-37.